Alvion to offer Ticagrelor film-coated tablets
Alvion Pharmaceuticals has completed the development of the EU eCTD dossier of Ticagrelor film-coated tablets.
The product is a generic medicine equivalent to Brilique of AstraZeneca, reducing the risk of MACE (major adverse cardiac events) in myocardial infarction patients (source: Journal of the American College of Cardiology). It is a lifesaving therapy used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, such as problems with blood supply in the coronary arteries.
Alvion expects to be among the first companies to offer Ticagrelor in Europe to its partners across the world, aiming to penetrate significant market share in Europe, MENA and other territories following its patent expiry.
“Alvion Pharmaceuticals is pleased to offer a successfully completed development of Ticagrelor, produced in a state-of-the-art facility. Through our out-licensing agreements, we offer important proprietaries to leading pharmaceutical companies, focusing on delivering on time and at a competitive cost. At Alvion we focus on the cardiovascular therapeutic category, offering high-quality medicines to our partners while significantly investing in fixed-combination technologies as well as extended-release formulations.”
John Bouros — Chief Executive Officer, Alvion Pharmaceuticals
About Alvion
Alvion Pharmaceuticals S.M.S.A. (Alvion), Athens, Greece, is an international pharmaceutical company focusing on the development of added-value generic medicines in various therapeutic categories including but not limited to cardiovascular, diabetes, urinary and central nervous system. With sales in more than 40 countries, Alvion licenses its products to the leading pharmaceutical companies across the world.
Enquiries
For more information, please visit alvionpharma.com or contact us at partnering@alvionpharma.com.